In this issue of Blood, Pidala et al 1 report the results of a pioneering phase 1 trial demonstrating that antigen-specific expanded regulatory T cells (Tregs) can safely be applied as a promising new strategy for preventing graftversus-host disease (GVHD) in patients undergoing matched sibling allogeneic hematopoietic cell transplantation (HCT).
No takes yet. Share an insight, caveat, or question.
Bornhäuser et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: